Legend Biotech (LEGN) Misses Q4 EPS by 6c

Legend Biotech (NASDAQ: LEGN) reported Q4 EPS of ($0.40), $0.06 worse than the analyst estimate of ($0.34). Revenue for the quarter came in at $79.46 million versus the consensus estimate of $94.07 million.

For earnings history and earnings-related data on Legend Biotech (LEGN) click here.

You May Also Be Interested In

• H&R Block (HRB) Tops Q4 EPS by 7c, Offers Guidance
• Mount Logan Capital Inc. (MLCI) Reports Q2 Loss of $0.37
• Snail, Inc. (SNAL) Reports Q3 Loss of $0.36